Status:
COMPLETED
A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects
Lead Sponsor:
Syntrix Biosystems, Inc.
Collaborating Sponsors:
Celerion
National Institute on Drug Abuse (NIDA)
Conditions:
Pain
Eligibility:
All Genders
19-55 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to investigate in healthy human subjects how much desmetramadol (Omnitram) gets in the blood after different oral doses are taken with or without food.
Detailed Description
An open-label, randomized, balanced, single-dose, four-treatment, four-period, four-sequence (using a Williams' square design) cross-over study with each dose separated by \>3 days. There are 4 sequen...
Eligibility Criteria
Inclusion
- Healthy males and females with vital signs as follows at screening: systolic blood pressure \> 90 mm Hg and \< 140 mm Hg; diastolic blood pressure \> 40 mm Hg and \< 90 mm Hg; pulse 40 to 99 beats per minute; respiratory rate 12 to 24 breathes per minute.
- Age 19 to 55 years.
- Able and willing to give informed consent
- Able to comply with all study procedures.
- If female, must not be of childbearing potential or must agree to use one or more of the following forms of contraception from screening, throughout the study and for 30 days following study drug administration: hormonal (e.g., oral, transdermal, intravaginal, implant or injection for 3 months); double barrier (e.g., condom or diaphragm with spermicide); intrauterine device (IUD) or system (IUS) (for 3 months); vasectomized partner (6 months minimum); or abstinence.
- Screening laboratory results must be within normal range per clinical research unit: serum sodium, potassium, calcium, BUN, creatinine, ALT, AST, total bilirubin, alkaline phosphatase, glucose (random), albumin, total protein, WBC and differential, hemoglobin, and platelets. In addition PT and PTT must be \< 1.2 ULN.
- Electrocardiogram (ECG) without clinically significant abnormalities.
- Urinalysis demonstrating \< +1 glucose, and +1 protein.
- If female, must have a negative pregnancy test at screening
- Negative urine test for substances of abuse, including opiates, per clinical pharmacology unit standards at screening and clinic check-in.
- Negative serology tests for HIV, hepatitis B surface antigen, and hepatitis C virus antibody.
- Weight \> 50 Kg and a body mass index (BMI) of 18.0 to 32.0 kg/m (inclusive).
- Non-smoker of tobacco for a minimum of the past 3 months, and negative urine continine test.
Exclusion
- Oral temperature \> 38°C or current illness.
- History of seizures, epilepsy, or recognized increase risk of seizure (e.g., head trauma, metabolic disorders, alcohol or drug withdrawal).
- History of cirrhosis or laboratory evidence of liver disease.
- Having undergone gall bladder removal.
- Use of alcohol within 24 hours of day -1 until the end of the study; and grapefruit, grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), or grapefruit juice or grapefruit-related juices within 7 days of study drug administration and until the end of the study.
- History of previous anaphylaxis, severe allergic reaction to tramadol, codeine, or other opioid drugs.
- Any other unstable acute or chronic disease that could interfere with the evaluation of the safety of the study drug as determined by the principal Investigator in dialogue with the Sponsor Medical Monitor.
- Females must not be currently pregnant or breast feeding.
- Unlikely to comply with the study protocol.
- Known or suspected alcohol or drug abuse within the past 6 months.
- Received another investigational agent within 4 weeks of Day -1, or within five half-lives of Day -1, whichever is longer; or receiving any other investigational agent during this study.
- Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which, in the Investigator's opinion, could compromise compliance with the objectives and procedures of this protocol, or obscure interpretation of the trial data.
Key Trial Info
Start Date :
January 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 18 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04683926
Start Date
January 8 2021
End Date
January 18 2021
Last Update
April 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion
Lincoln, Nebraska, United States, 68502